TIALD and hepatocellular carcinoma: More importantly, previous studies showing alisertib exhibited remarkable anticancer effects in preclinical studies and in Phase I and II trials [31], and the low risk of side effects, accessibility, and effectiveness of alisertib makes it a new promising anticancer therapy with further mechanistic and clinical studies, and our study shows that Alisertib may be a drug with great therapeutic potential in TIALD low expressed HCC.